Molbio Diagnostics IPO: Temasek-Backed Healthcare Pioneer Seeks ₹12,000 Crore Valuation
When a new milestone is created between healthcare and finance, the curiosity of both investors and the general public increases. Something similar is happening now with the Molbio Diagnostics IPO, a name that is seen as a strong and trusted player in India’s healthcare diagnostics industry. With backing from Temasek Holdings and Motilal Oswal Private Equity, this Goa-based diagnostics company is approaching its Initial Public Offering (IPO) and its valuation has reached almost ₹12,000 crore.
Molbio Diagnostics IPO: What is the company’s plan?
Molbio Diagnostics has filed its preliminary papers with SEBI in which the company has indicated its readiness to raise funds through an IPO. According to the draft papers, this IPO will include both a fresh issue and an offer-for-sale (OFS). The company will raise ₹200 crore through the fresh issue, while the rest of the money will come through offer-for-sale.
Around 1.25 crore equity shares will be sold in the offer-for-sale in which both promoters and existing investors will offload their stake. Exxora Trading LLP and Chandrasekhar Bhaskaran Nair, who hold 46.65% stake in the company, will sell their 29.12 lakh shares. On the other hand, big investors like Temasek-backed V Sciences Investments and Motilal Oswal’s India Business Excellence Fund III will sell their stake.
Molbio Diagnostics IPO: Investors and Shareholding Structure
As of now, the major investors of Molbio Diagnostics include India Business Excellence Fund III (managed by Motilal Oswal PE) and V-Sciences Investments (subsidiary of Temasek Holdings). Both of them are big players who had invested in the company between January 2021 and September 2022.
According to the company’s papers, the last transaction took place on July 14, 2025 when Shruthi G Kini transferred some of her shares at the rate of Rs 5,450 per share. After this, the company announced a bonus issue on July 29, 2025 in which 4 new equity shares were given in exchange for every 1 equity share. After the bonus issue, the adjusted share price became ₹1,090 per share, taking the company’s valuation to approximately ₹12,490 crore.
Molbio Diagnostics IPO: Innovation and Future of Healthcare
Molbio Diagnostics is known for its innovation and technology-driven approach. The company’s biggest contribution is the Truenat platform, a Point-of-Care (POC) polymerase chain reaction (PCR) testing platform. The platform provides rapid and affordable diagnostic solutions and has so far developed molecular testing solutions for 30 different diseases.
The biggest thing is that the Truenat platform is one of only two rapid molecular test solutions in the world to diagnose TB, and is India’s only indigenous solution. This factor gives Molbio an oligopolistic market position where entry barriers are quite high.
Molbio Diagnostics IPO: Utilisation of Funds
The company has also given a clear breakup of the ₹200 crore raised from the fresh issue of the IPO. Approximately ₹99.37 crore will be invested in setting up R&D infrastructure, a Centre of Excellence and new office space. Also, ₹73.6 crore will be invested in purchasing plant, machinery and equipment for Goa Unit I & II and Visakhapatnam Unit. The remaining money will be used for general corporate purposes.
This kind of utilisation plan is a positive signal for investors as it shows that the company is focusing on long-term growth and innovation.
Molbio Diagnostics IPO: Strong Financial Performance
Molbio Diagnostics has made its track record impressive from the angle of financial performance as well. In the results of FY2025, the company has shown profit growth of up to 66%, with net profit reaching ₹138.6 crore. Revenue has also jumped 22% to ₹1,020.4 crore.
These numbers clearly show that the company is not only sustainable but is also on a growth trajectory. Such a solid performance in a competitive sector like healthcare diagnostics can be a major confidence booster for investors.
Molbio Diagnostics IPO: Merchant Bankers
The merchant bankers chosen by Molbio Diagnostics for its IPO include Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors. All these names are known for their expertise and credibility and their role will be to properly showcase the IPO to investors, create demand in the market and manage the process smoothly. When such reputed bankers are involved, the transparency and chances of success of the IPO also increase.
Final Thoughts on Molbio Diagnostics IPO
Today, healthcare and diagnostics is one such sector which is growing at a rapid pace. People’s awareness towards health and early diagnosis is increasing, and due to this the importance of companies like Molbio Diagnostics has increased even more. With its Truenat technology, strong financial results and innovation-led approach, the company has created a unique position for itself.
Backing of big investors like Temasek and Motilal Oswal gives more credibility to the company, which makes the IPO even stronger. That is, on one hand you get a healthcare pioneer who provides life-saving solutions through technology, and on the other hand strong investors and bankers who are supporting the IPO.
This IPO can be an interesting opportunity for investors, but always remember that every investment carries risk. If your focus is on the healthcare sector and you trust growth-oriented companies, then Molbio Diagnostics IPO should definitely be on your watchlist. Just consult your financial advisor while taking the final decision and do not forget to keep your risk appetite in mind.
Disclaimer:
This article is for informational purposes only. We are not giving any financial advice. Always seek advice from your financial advisor before taking an investment decision.
Also Read
Upcoming IPOs 2025: Vikran Engineering, Anlon Healthcare & Other Hot Public Issues Next Week
